Log in to save to my catalogue

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ee6656f7232f43be80a2f6cd65a8083d

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

About this item

Full title

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Publisher

England: BioMed Central Ltd

Journal title

Journal of experimental & clinical cancer research, 2021-01, Vol.40 (1), p.15-15, Article 15

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to increase the activity of DNA damaging chemotherapeutics used...

Alternative Titles

Full title

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ee6656f7232f43be80a2f6cd65a8083d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ee6656f7232f43be80a2f6cd65a8083d

Other Identifiers

ISSN

1756-9966,0392-9078

E-ISSN

1756-9966

DOI

10.1186/s13046-020-01811-8

How to access this item